Characterization of ex vivo expanded tumor infiltrating lymphocytes from patients with malignant melanoma for clinical application

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

Characterization of ex vivo expanded tumor infiltrating lymphocytes from patients with malignant melanoma for clinical application. / Junker, Niels; Thor Straten, Per; Andersen, Mads Hald; Svane, Inge Marie.

I: Journal of Skin Cancer, Bind 2011, Nr. 574695, 2011.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Junker, N, Thor Straten, P, Andersen, MH & Svane, IM 2011, 'Characterization of ex vivo expanded tumor infiltrating lymphocytes from patients with malignant melanoma for clinical application', Journal of Skin Cancer, bind 2011, nr. 574695. https://doi.org/10.1155/2011/574695

APA

Junker, N., Thor Straten, P., Andersen, M. H., & Svane, I. M. (2011). Characterization of ex vivo expanded tumor infiltrating lymphocytes from patients with malignant melanoma for clinical application. Journal of Skin Cancer, 2011(574695). https://doi.org/10.1155/2011/574695

Vancouver

Junker N, Thor Straten P, Andersen MH, Svane IM. Characterization of ex vivo expanded tumor infiltrating lymphocytes from patients with malignant melanoma for clinical application. Journal of Skin Cancer. 2011;2011(574695). https://doi.org/10.1155/2011/574695

Author

Junker, Niels ; Thor Straten, Per ; Andersen, Mads Hald ; Svane, Inge Marie. / Characterization of ex vivo expanded tumor infiltrating lymphocytes from patients with malignant melanoma for clinical application. I: Journal of Skin Cancer. 2011 ; Bind 2011, Nr. 574695.

Bibtex

@article{e46fdaf86f2e492bace71eda7dd5ea8f,
title = "Characterization of ex vivo expanded tumor infiltrating lymphocytes from patients with malignant melanoma for clinical application",
abstract = "Clinical trials of adoptive transfer of autologous tumor infiltrating lymphocytes (TILs) to patients with advanced malignant melanoma have shown remarkable results with objective clinical responses in 50% of the treated patients. In order to initiate a clinical trial in melanoma, we have established a method for expanding TILs to clinical relevant quantities in two steps with in 8 weeks. Further characterization of expanded TILs revealed an oligoclonal composition of T-cells with an effector memory like phenotype. When autologous tumor was available, TILs showed specific activity in all patients tested. TIL cultures contained specificity towards tumor cells as well as peptides derived from tumor-associated antigens (TAAs) during expansion procedures.",
author = "Niels Junker and {Thor Straten}, Per and Andersen, {Mads Hald} and Svane, {Inge Marie}",
year = "2011",
doi = "http://dx.doi.org/10.1155/2011/574695",
language = "English",
volume = "2011",
journal = "Journal of Skin Cancer",
issn = "2090-2905",
publisher = "Hindawi Publishing Corporation",
number = "574695",

}

RIS

TY - JOUR

T1 - Characterization of ex vivo expanded tumor infiltrating lymphocytes from patients with malignant melanoma for clinical application

AU - Junker, Niels

AU - Thor Straten, Per

AU - Andersen, Mads Hald

AU - Svane, Inge Marie

PY - 2011

Y1 - 2011

N2 - Clinical trials of adoptive transfer of autologous tumor infiltrating lymphocytes (TILs) to patients with advanced malignant melanoma have shown remarkable results with objective clinical responses in 50% of the treated patients. In order to initiate a clinical trial in melanoma, we have established a method for expanding TILs to clinical relevant quantities in two steps with in 8 weeks. Further characterization of expanded TILs revealed an oligoclonal composition of T-cells with an effector memory like phenotype. When autologous tumor was available, TILs showed specific activity in all patients tested. TIL cultures contained specificity towards tumor cells as well as peptides derived from tumor-associated antigens (TAAs) during expansion procedures.

AB - Clinical trials of adoptive transfer of autologous tumor infiltrating lymphocytes (TILs) to patients with advanced malignant melanoma have shown remarkable results with objective clinical responses in 50% of the treated patients. In order to initiate a clinical trial in melanoma, we have established a method for expanding TILs to clinical relevant quantities in two steps with in 8 weeks. Further characterization of expanded TILs revealed an oligoclonal composition of T-cells with an effector memory like phenotype. When autologous tumor was available, TILs showed specific activity in all patients tested. TIL cultures contained specificity towards tumor cells as well as peptides derived from tumor-associated antigens (TAAs) during expansion procedures.

U2 - http://dx.doi.org/10.1155/2011/574695

DO - http://dx.doi.org/10.1155/2011/574695

M3 - Journal article

VL - 2011

JO - Journal of Skin Cancer

JF - Journal of Skin Cancer

SN - 2090-2905

IS - 574695

ER -

ID: 40197080